1|Page
TEST BANK: PHARMACOTHERAPEUTICS
FOR ADVANCED PRACTICE – A PRACTICAL
APPROACH
## Table of Contents
| Section | Topic | Question Count |
|---------|-------|----------------|
| 1 | Pharmacokinetics & Pharmacodynamics | 25 |
| 2 | Medication Safety & Prescribing | 20 |
| 3 | Autonomic & CNS Drugs | 30 |
| 4 | Cardiovascular Drugs | 30 |
| 5 | Anti-infectives | 25 |
| 6 | Endocrine & Diabetes | 25 |
| 7 | Respiratory, GI, & Rheumatology | 25 |
| 8 | Special Populations (Peds, Geri, Pregnancy) | 20 |
| 9 | High-Yield Clinical Cases | 10 |
| **Total** | | **210** |
---
,2|Page
# SECTION 1: Pharmacokinetics & Pharmacodynamics (25 Questions)
**1. A patient with end-stage renal disease (ESRD) is prescribed a
medication that is 70% renally excreted. Which pharmacokinetic change
is most expected?**
A. Decreased volume of distribution
B. Increased half-life
C. Decreased bioavailability
D. Increased protein binding
**Answer: B – Increased half-life**
*Rationale:* Reduced renal clearance leads to drug accumulation and
prolonged half-life. Volume of distribution may increase due to fluid
shifts, not decrease. Bioavailability may be altered but not primarily due
to excretion changes.
**2. A drug follows first-order kinetics. After one half-life, what
percentage of the drug remains in the body?**
A. 25%
B. 50%
C. 75%
D. 100%
**Answer: B – 50%**
,3|Page
*Rationale:* First-order kinetics: constant fraction eliminated per unit
time. Each half-life reduces the remaining drug by 50%.
**3. Which statement best describes a competitive antagonist?**
A. Binds irreversibly to the receptor
B. Decreases maximal efficacy (Emax)
C. Shifts dose-response curve to the right without reducing Emax
D. Requires new receptor synthesis for reversal
**Answer: C**
*Rationale:* Competitive antagonists bind reversibly to the same
receptor site, requiring higher agonist concentration to achieve same
effect (rightward shift). Emax unchanged.
**4. A drug has a volume of distribution (Vd) of 500 L. This suggests:**
A. The drug is highly protein bound
B. The drug is confined to the vascular space
C. The drug is extensively distributed into tissues
D. The drug is renally excreted
**Answer: C**
, 4|Page
*Rationale:* High Vd (>42 L total body water) indicates extensive tissue
distribution. Low Vd suggests confinement to plasma or extracellular
fluid.
**5. Which cytochrome P450 enzyme is most commonly involved in
clinically significant drug-drug interactions?**
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4
**Answer: D – CYP3A4**
*Rationale:* CYP3A4 metabolizes >50% of all drugs. Inducers
(rifampin, St. John’s wort) and inhibitors (grapefruit juice, ketoconazole)
cause major interactions.
**6. A patient is taking a drug with a narrow therapeutic index. Which
statement is correct?**
A. Small changes in dose rarely cause toxicity
B. Therapeutic drug monitoring is strongly recommended
C. The drug has a wide safety margin
D. Generic substitution is always safe
**Answer: B**
TEST BANK: PHARMACOTHERAPEUTICS
FOR ADVANCED PRACTICE – A PRACTICAL
APPROACH
## Table of Contents
| Section | Topic | Question Count |
|---------|-------|----------------|
| 1 | Pharmacokinetics & Pharmacodynamics | 25 |
| 2 | Medication Safety & Prescribing | 20 |
| 3 | Autonomic & CNS Drugs | 30 |
| 4 | Cardiovascular Drugs | 30 |
| 5 | Anti-infectives | 25 |
| 6 | Endocrine & Diabetes | 25 |
| 7 | Respiratory, GI, & Rheumatology | 25 |
| 8 | Special Populations (Peds, Geri, Pregnancy) | 20 |
| 9 | High-Yield Clinical Cases | 10 |
| **Total** | | **210** |
---
,2|Page
# SECTION 1: Pharmacokinetics & Pharmacodynamics (25 Questions)
**1. A patient with end-stage renal disease (ESRD) is prescribed a
medication that is 70% renally excreted. Which pharmacokinetic change
is most expected?**
A. Decreased volume of distribution
B. Increased half-life
C. Decreased bioavailability
D. Increased protein binding
**Answer: B – Increased half-life**
*Rationale:* Reduced renal clearance leads to drug accumulation and
prolonged half-life. Volume of distribution may increase due to fluid
shifts, not decrease. Bioavailability may be altered but not primarily due
to excretion changes.
**2. A drug follows first-order kinetics. After one half-life, what
percentage of the drug remains in the body?**
A. 25%
B. 50%
C. 75%
D. 100%
**Answer: B – 50%**
,3|Page
*Rationale:* First-order kinetics: constant fraction eliminated per unit
time. Each half-life reduces the remaining drug by 50%.
**3. Which statement best describes a competitive antagonist?**
A. Binds irreversibly to the receptor
B. Decreases maximal efficacy (Emax)
C. Shifts dose-response curve to the right without reducing Emax
D. Requires new receptor synthesis for reversal
**Answer: C**
*Rationale:* Competitive antagonists bind reversibly to the same
receptor site, requiring higher agonist concentration to achieve same
effect (rightward shift). Emax unchanged.
**4. A drug has a volume of distribution (Vd) of 500 L. This suggests:**
A. The drug is highly protein bound
B. The drug is confined to the vascular space
C. The drug is extensively distributed into tissues
D. The drug is renally excreted
**Answer: C**
, 4|Page
*Rationale:* High Vd (>42 L total body water) indicates extensive tissue
distribution. Low Vd suggests confinement to plasma or extracellular
fluid.
**5. Which cytochrome P450 enzyme is most commonly involved in
clinically significant drug-drug interactions?**
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4
**Answer: D – CYP3A4**
*Rationale:* CYP3A4 metabolizes >50% of all drugs. Inducers
(rifampin, St. John’s wort) and inhibitors (grapefruit juice, ketoconazole)
cause major interactions.
**6. A patient is taking a drug with a narrow therapeutic index. Which
statement is correct?**
A. Small changes in dose rarely cause toxicity
B. Therapeutic drug monitoring is strongly recommended
C. The drug has a wide safety margin
D. Generic substitution is always safe
**Answer: B**
